Maki Urushihara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maki Urushihara has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
Shoji Kagami
Department of Pediatrics, Institute of Health Biosciences The Tokushima University Graduate School Tokushima Japan
8 shared publicationsShuji Kondo
Department of Pediatrics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
6 shared publicationsTakashi Nagai
Department of Pediatrics, Institute of Health Biosciences The Tokushima University Graduate School Tokushima Japan
4 shared publicationsYukiko Kinoshita
Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan
4 shared publicationsAriunbold Jamba
Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan
3 shared publicationsKeisuke Fujioka
Department of Pediatrics, Institute of Health Biosciences The Tokushima University Graduate School Tokushima Japan
3 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (7) , 1-14
Clinical practice guideline for pediatric IgA vasculitis in Japan 2023: a digest-secondary publication
- 22 April 2026
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (7) , 1-14
Open AccessClinical practice guideline for pediatric IgA vasculitis in Japan 2023: a digest-secondary publication
- Open Access
- 1 January 2025
- Published by University of Tokushima Faculty of Medicine in The Journal of Medical Investigation
- Vol. 72 (3.4) , 241-244
The role of the renin-angiotensin system in pediatric kidney diseases and neonatal development
The local renal renin-angiotensin system (RAS) is regulated independently of the systemic RAS. The renal RAS not only regulates blood pressure and hemodynamics but also plays an important role in the kidney disease development. Many studies have shown that the of angiotensinogen urinary excretion rate is a specific index of the intrarenal RAS activation. Moreover, urinary angiotensinogen (AGT) levels reflect the intrarenal RAS status associated with hypertension, chronic kidney disease, and diabetic nephropathy. In addition, urinary AGT is a novel biomarker of intrarenal RAS activation during neonatal kidney development. Furthermore, angiotensin-converting enzyme 2 and the (pro)renin receptor have recently been identified as new components of the RAS that have novel functions in kidney diseases and development. This review summarizes the current knowledge on intrarenal RAS activation in the context of pathological and physiological processes in children. J. Med. Invest. 72 : 241-244, August, 2025
- 1 January 2025
- Published by University of Tokushima Faculty of Medicine in The Journal of Medical Investigation
- Vol. 72 (3.4) , 241-244
Open AccessThe role of the renin-angiotensin system in pediatric kidney diseases and neonatal development
The local renal renin-angiotensin system (RAS) is regulated independently of the systemic RAS. The renal RAS not only regulates blood pressure and hemodynamics but also plays an important role in the kidney disease development. Many studies have shown that the of angiotensinogen urinary excretion rate is a specific index of the intrarenal RAS activation. Moreover, urinary angiotensinogen (AGT) levels reflect the intrarenal RAS status associated with hypertension, chronic kidney disease, and diabetic nephropathy. In addition, urinary AGT is a novel biomarker of intrarenal RAS activation during neonatal kidney development. Furthermore, angiotensin-converting enzyme 2 and the (pro)renin receptor have recently been identified as new components of the RAS that have novel functions in kidney diseases and development. This review summarizes the current knowledge on intrarenal RAS activation in the context of pathological and physiological processes in children. J. Med. Invest. 72 : 241-244, August, 2025
- Open Access
- 1 January 2025
- Published by Japanese Society for Pediatric Nephrology in Japanese journal of pediatric nephrology
- Vol. 38, cr.24-026
A case of recurrent systemic lupus erythematosus in a boy with antiphospholipid syndrome nephropathy
症例は16歳,男子.2年前に全身性エリテマトーデス,ループス腎炎class IV-G(A)と診断した.メチルプレドニゾロンパルス療法,経口プレドニゾロン(PSL),ヒドロキシクロロキン(HCQ),ミコフェノール酸モフェチル(MMF)を併用し寛解に至るも,7か月後より治療を自己中断した.その1年後に発熱,全身浮腫をきたし当院を受診した.高血圧,腎機能障害,高度蛋白尿を認め,腎病理組織はclass IV-G(A)で血管極や係蹄内の血栓,フィブリノイド壊死が認められた.溶血性貧血の所見はなかったが,血栓性微小血管障害症,つまり抗リン脂質抗体症候群腎症(APSN)に特徴的な所見であった.PSLを開始,メチルプレドニゾロンパルス療法3クールを施行した.寛解維持のためHCQ, MMFも追加し,再発後約1年半が経過した現在も内服継続中である.本症例では腎機能障害が遷延しており,慢性腎臓病への移行が懸念される.
- 1 January 2025
- Published by Japanese Society for Pediatric Nephrology in Japanese journal of pediatric nephrology
- Vol. 38, cr.24-026
Open AccessA case of recurrent systemic lupus erythematosus in a boy with antiphospholipid syndrome nephropathy
症例は16歳,男子.2年前に全身性エリテマトーデス,ループス腎炎class IV-G(A)と診断した.メチルプレドニゾロンパルス療法,経口プレドニゾロン(PSL),ヒドロキシクロロキン(HCQ),ミコフェノール酸モフェチル(MMF)を併用し寛解に至るも,7か月後より治療を自己中断した.その1年後に発熱,全身浮腫をきたし当院を受診した.高血圧,腎機能障害,高度蛋白尿を認め,腎病理組織はclass IV-G(A)で血管極や係蹄内の血栓,フィブリノイド壊死が認められた.溶血性貧血の所見はなかったが,血栓性微小血管障害症,つまり抗リン脂質抗体症候群腎症(APSN)に特徴的な所見であった.PSLを開始,メチルプレドニゾロンパルス療法3クールを施行した.寛解維持のためHCQ, MMFも追加し,再発後約1年半が経過した現在も内服継続中である.本症例では腎機能障害が遷延しており,慢性腎臓病への移行が懸念される.
- 30 September 2024
- Published by Wiley in Nephrology
- Vol. 29 (12) , 815-824
Renin‐angiotensin blockade ameliorates the progression of glomerular injury in podocyte‐specific Ctcf knockout mice
Aim: Several studies have shown that the progression of proteinuria and renal tissue injury is associated with activation of the intrarenal renin‐angiotensin system (RAS). CCCTC‐binding factor (CTCF) is a DNA‐binding factor that plays an essential role in the regulation of gene expression. In the present study, we aimed to investigate the phenotypic effects of CTCF deficiency in podocytes.Methods: Angiotensin II type 1 receptor blockers (ARBs) were administered to the podocyte‐specific Ctcf knockout mice, and histological and biochemical analyzes were performed. We also investigated the changes in the expression of podocin in podocyte cell cultures with or without stimulation with angiotensin II from glomeruli isolated using magnetic beads from podocyte‐specific Ctcf knockout mice.Results: Mice in which Ctcf was deleted from podocytes developed glomerulopathy and mice developed severe progressive proteinuria, and impaired renal function. Moreover, ARBs suppressed the development of glomerulopathy in podocyte‐specific Ctcf knockout mice. Both real‐time polymerase chain reaction and western blotting showed that podocin expression was decreased in cell cultures stimulated with angiotensin II. Furthermore, RAS components gene expressions in podocyte cell cultures isolated from podocyte‐specific Ctcf knockout mice were significantly increased.Conclusion: These results suggest that RAS is involved in the development of glomerulopathy in podocyte‐specific Ctcf knockout mice. Elucidation of the pathophysiology of podocyte‐specific Ctcf knockout mice may provide new insights into the relationship between podocyte injury and chronic glomerulonephritis. image
- 30 September 2024
- Published by Wiley in Nephrology
- Vol. 29 (12) , 815-824
Renin‐angiotensin blockade ameliorates the progression of glomerular injury in podocyte‐specific Ctcf knockout mice
Aim: Several studies have shown that the progression of proteinuria and renal tissue injury is associated with activation of the intrarenal renin‐angiotensin system (RAS). CCCTC‐binding factor (CTCF) is a DNA‐binding factor that plays an essential role in the regulation of gene expression. In the present study, we aimed to investigate the phenotypic effects of CTCF deficiency in podocytes.Methods: Angiotensin II type 1 receptor blockers (ARBs) were administered to the podocyte‐specific Ctcf knockout mice, and histological and biochemical analyzes were performed. We also investigated the changes in the expression of podocin in podocyte cell cultures with or without stimulation with angiotensin II from glomeruli isolated using magnetic beads from podocyte‐specific Ctcf knockout mice.Results: Mice in which Ctcf was deleted from podocytes developed glomerulopathy and mice developed severe progressive proteinuria, and impaired renal function. Moreover, ARBs suppressed the development of glomerulopathy in podocyte‐specific Ctcf knockout mice. Both real‐time polymerase chain reaction and western blotting showed that podocin expression was decreased in cell cultures stimulated with angiotensin II. Furthermore, RAS components gene expressions in podocyte cell cultures isolated from podocyte‐specific Ctcf knockout mice were significantly increased.Conclusion: These results suggest that RAS is involved in the development of glomerulopathy in podocyte‐specific Ctcf knockout mice. Elucidation of the pathophysiology of podocyte‐specific Ctcf knockout mice may provide new insights into the relationship between podocyte injury and chronic glomerulonephritis. image
- 12 March 2024
- Published by Elsevier in Brain and Development
- Vol. 46 (6) , 230-233
A female case of L1 syndrome that may have developed due to skewed X inactivation
- 12 March 2024
- Published by Elsevier in Brain and Development
- Vol. 46 (6) , 230-233
A female case of L1 syndrome that may have developed due to skewed X inactivation
- Open Access
- 25 May 2023
- Published by Springer Nature in Pediatric Nephrology
- Vol. 38 (11) , 3711-3719
Intrarenal renin–angiotensin system activation and macrophage infiltrations in pediatric chronic glomerulonephritis
Background: The current study tested the hypothesis that urinary angiotensinogen (UAGT) and urinary monocyte chemoattractant protein-1 (UMCP-1) levels provide a specific index of intrarenal renin–angiotensin system (RAS) status and the degree of infiltration of macrophages associated with RAS blockade and immunosuppressant treatment in pediatric patients with chronic glomerulonephritis. Methods: We measured baseline UAGT and UMCP-1 levels to examine the correlation between glomerular injury in 48 pediatric chronic glomerulonephritis patients before treatment. Furthermore, we performed immunohistochemical analysis of angiotensinogen (AGT) and CD68 in 27 pediatric chronic glomerulonephritis patients treated with RAS blockades and immunosuppressants for 2 years. Finally, we examined the effects of angiotensin II (Ang II) on monocyte chemoattractant protein-1 (MCP-1) expression in cultured human mesangial cells (MCs). Results: Baseline UAGT and UMCP-1 levels positively correlated with urinary protein levels, scores for mesangial hypercellularity, rate of crescentic formation, and expression levels of AGT and CD68 in renal tissues (p < 0.05). UAGT and UMCP-1 levels were significantly decreased after RAS blockade and immunosuppressant treatment (p < 0.01), which was accompanied by AGT and CD68 (p < 0.01), as well as the magnitude of glomerular injury. Cultured human MCs showed increased MCP-1 messenger ribonucleic acid and protein levels after Ang II treatment (p < 0.01). Conclusions: The data indicates that UAGT and UMCP-1 are useful biomarkers of the degree of glomerular injury during RAS blockade and immunosuppressant treatment in pediatric patients with chronic glomerulonephritis.
- 25 May 2023
- Published by Springer Nature in Pediatric Nephrology
- Vol. 38 (11) , 3711-3719
Open AccessIntrarenal renin–angiotensin system activation and macrophage infiltrations in pediatric chronic glomerulonephritis
Background: The current study tested the hypothesis that urinary angiotensinogen (UAGT) and urinary monocyte chemoattractant protein-1 (UMCP-1) levels provide a specific index of intrarenal renin–angiotensin system (RAS) status and the degree of infiltration of macrophages associated with RAS blockade and immunosuppressant treatment in pediatric patients with chronic glomerulonephritis. Methods: We measured baseline UAGT and UMCP-1 levels to examine the correlation between glomerular injury in 48 pediatric chronic glomerulonephritis patients before treatment. Furthermore, we performed immunohistochemical analysis of angiotensinogen (AGT) and CD68 in 27 pediatric chronic glomerulonephritis patients treated with RAS blockades and immunosuppressants for 2 years. Finally, we examined the effects of angiotensin II (Ang II) on monocyte chemoattractant protein-1 (MCP-1) expression in cultured human mesangial cells (MCs). Results: Baseline UAGT and UMCP-1 levels positively correlated with urinary protein levels, scores for mesangial hypercellularity, rate of crescentic formation, and expression levels of AGT and CD68 in renal tissues (p < 0.05). UAGT and UMCP-1 levels were significantly decreased after RAS blockade and immunosuppressant treatment (p < 0.01), which was accompanied by AGT and CD68 (p < 0.01), as well as the magnitude of glomerular injury. Cultured human MCs showed increased MCP-1 messenger ribonucleic acid and protein levels after Ang II treatment (p < 0.01). Conclusions: The data indicates that UAGT and UMCP-1 are useful biomarkers of the degree of glomerular injury during RAS blockade and immunosuppressant treatment in pediatric patients with chronic glomerulonephritis.
- 28 May 2021
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 25 (9) , 1018-1026
Clinical and histological features in pediatric and adolescent/young adult patients with renal disease: a cross-sectional analysis of the Japan Renal Biopsy Registry (J-RBR)
Background Only a few studies have investigated epidemiological and clinicopathological information regarding pediatric and adolescent and young adult (AYA) patients with renal disease. The purpose of this study was to clarify the differences and relationship of clinicopathological findings between pediatric and AYA patients using the Japan Renal Biopsy Registry (J-RBR). Methods This cross-sectional study analyzed data from patients registered in the J-RBR between 2007 and 2017. Clinicopathological findings at diagnosis were analyzed for 3,463 pediatric (age < 15 years) and 6,532 AYA (age 15–30 years) patients. Results Although chronic nephritic syndrome was the most common clinical diagnosis at age > 5 years, nephrotic syndrome was the most frequent diagnosis at age < 4 years. The most common pathological diagnosis as classified by pathogenesis in pediatric patients was primary glomerular disease (except IgA nephropathy), whereas IgA nephropathy was increased in AYA patients. Mesangial proliferative glomerulonephritis was the most common pathological diagnosis as classified by histopathology in both pediatric and AYA patients. Minor glomerular abnormalities were the most frequent histopathologic diagnoses of nephrotic syndrome in childhood, but their frequency decreased with age. Conclusion To the best of our knowledge, this is the first report of clinicopathological features of pediatric and AYA patients in a large nationwide registry of renal biopsy. There were differences of clinical, pathological and histopathologic findings between pediatric and AYA patients.
- 28 May 2021
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 25 (9) , 1018-1026
Clinical and histological features in pediatric and adolescent/young adult patients with renal disease: a cross-sectional analysis of the Japan Renal Biopsy Registry (J-RBR)
Background Only a few studies have investigated epidemiological and clinicopathological information regarding pediatric and adolescent and young adult (AYA) patients with renal disease. The purpose of this study was to clarify the differences and relationship of clinicopathological findings between pediatric and AYA patients using the Japan Renal Biopsy Registry (J-RBR). Methods This cross-sectional study analyzed data from patients registered in the J-RBR between 2007 and 2017. Clinicopathological findings at diagnosis were analyzed for 3,463 pediatric (age < 15 years) and 6,532 AYA (age 15–30 years) patients. Results Although chronic nephritic syndrome was the most common clinical diagnosis at age > 5 years, nephrotic syndrome was the most frequent diagnosis at age < 4 years. The most common pathological diagnosis as classified by pathogenesis in pediatric patients was primary glomerular disease (except IgA nephropathy), whereas IgA nephropathy was increased in AYA patients. Mesangial proliferative glomerulonephritis was the most common pathological diagnosis as classified by histopathology in both pediatric and AYA patients. Minor glomerular abnormalities were the most frequent histopathologic diagnoses of nephrotic syndrome in childhood, but their frequency decreased with age. Conclusion To the best of our knowledge, this is the first report of clinicopathological features of pediatric and AYA patients in a large nationwide registry of renal biopsy. There were differences of clinical, pathological and histopathologic findings between pediatric and AYA patients.
- 1 October 2020
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 319 (4) , F571-F578
(Pro)renin receptor promotes crescent formation via the ERK1/2 and Wnt/β-catenin pathways in glomerulonephritis
(Pro)renin receptor [(P)RR] has multiple functions, but its regulation and role in the pathogenesis in glomerulonephritis (GN) are poorly defined. The aims of the present study were to determine the effects of direct renin inhibition (DRI) and demonstrate the role of (P)RR on the progression of crescentic GN. The anti-glomerular basement membrane nephritis rat model developed progressive proteinuria (83.64 ± 10.49 mg/day) and glomerular crescent formation (percent glomerular crescent: 62.1 ± 2.3%) accompanied by increased macrophage infiltration and glomerular expression of monocyte chemoattractant protein (MCP)-1, (P)RR, phospho-extracellular signal-regulated kinase (ERK)1/2, Wnt4, and active β-catenin. Treatment with DRI ameliorated proteinuria (20.33 ± 5.88 mg/day) and markedly reduced glomerular crescent formation (20.9 ± 2.6%), induction of macrophage infiltration, (P)RR, phospho-ERK1/2, Wnt4, and active β-catenin. Furthermore, primary cultured parietal epithelial cells stimulated by recombinant prorenin showed significant increases in cell proliferation. Notably, while the ERK1/2 inhibitor PD98059 or (P)RR-specific siRNA treatment abolished the elevation in cell proliferation, DRI treatment did not abrogate this elevation. Moreover, cultured mesangial cells showed an increase in prorenin-induced MCP-1 expression. Interestingly, (P)RR or Wnt4-specific siRNA treatment or the β-catenin antagonist XAV939 inhibited the elevation of MCP-1 expression, whereas DRI did not. These results suggest that (P)RR regulates glomerular crescent formation via the ERK1/2 signaling and Wnt/β-catenin pathways during the course of anti-glomerular basement membrane nephritis and that DRI mitigates the progression of crescentic GN through the reduction of (P)RR expression but not inhibition of prorenin binding to (P)RR.
- 1 October 2020
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 319 (4) , F571-F578
(Pro)renin receptor promotes crescent formation via the ERK1/2 and Wnt/β-catenin pathways in glomerulonephritis
(Pro)renin receptor [(P)RR] has multiple functions, but its regulation and role in the pathogenesis in glomerulonephritis (GN) are poorly defined. The aims of the present study were to determine the effects of direct renin inhibition (DRI) and demonstrate the role of (P)RR on the progression of crescentic GN. The anti-glomerular basement membrane nephritis rat model developed progressive proteinuria (83.64 ± 10.49 mg/day) and glomerular crescent formation (percent glomerular crescent: 62.1 ± 2.3%) accompanied by increased macrophage infiltration and glomerular expression of monocyte chemoattractant protein (MCP)-1, (P)RR, phospho-extracellular signal-regulated kinase (ERK)1/2, Wnt4, and active β-catenin. Treatment with DRI ameliorated proteinuria (20.33 ± 5.88 mg/day) and markedly reduced glomerular crescent formation (20.9 ± 2.6%), induction of macrophage infiltration, (P)RR, phospho-ERK1/2, Wnt4, and active β-catenin. Furthermore, primary cultured parietal epithelial cells stimulated by recombinant prorenin showed significant increases in cell proliferation. Notably, while the ERK1/2 inhibitor PD98059 or (P)RR-specific siRNA treatment abolished the elevation in cell proliferation, DRI treatment did not abrogate this elevation. Moreover, cultured mesangial cells showed an increase in prorenin-induced MCP-1 expression. Interestingly, (P)RR or Wnt4-specific siRNA treatment or the β-catenin antagonist XAV939 inhibited the elevation of MCP-1 expression, whereas DRI did not. These results suggest that (P)RR regulates glomerular crescent formation via the ERK1/2 signaling and Wnt/β-catenin pathways during the course of anti-glomerular basement membrane nephritis and that DRI mitigates the progression of crescentic GN through the reduction of (P)RR expression but not inhibition of prorenin binding to (P)RR.
- 23 October 2018
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 23 (4) , 537-543
Enhanced angiotensinogen expression in neonates during kidney development
We recently demonstrated that preterm neonates have higher urinary angiotensinogen (AGT) levels than full-term neonates. Here, we tested the hypothesis that enhanced neonatal AGT expression is associated with intrarenal renin–angiotensin system (RAS) status during kidney development.
- 23 October 2018
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 23 (4) , 537-543
Enhanced angiotensinogen expression in neonates during kidney development
We recently demonstrated that preterm neonates have higher urinary angiotensinogen (AGT) levels than full-term neonates. Here, we tested the hypothesis that enhanced neonatal AGT expression is associated with intrarenal renin–angiotensin system (RAS) status during kidney development.
- 15 June 2017
- Published by Wiley in Nephrology
- Vol. 22 (7) , 566-571
Diversity of renal phenotypes in patients with WDR19 mutations: Two case reports
WDR19 has been reported as a causative gene of nephronophthisis‐related ciliopathies. Patients with WDR19 mutations can show various extrarenal manifestations such as skeletal disorders, Caroli disease, and retinal dystrophy, and typically display nephronophthisis as a renal phenotype. However, there is limited information on the renal phenotypes of patients with WDR19 mutations. We report two Japanese infants with Sensenbrenner syndrome caused by WDR19 mutations who demonstrated different features in renal ultrasound and histopathological results, despite several common extrarenal manifestations. Patient 1 had normal sized and hyperechogenic kidneys with several small cysts and histopathological findings compatible with infantile nephronophthisis. Renal ultrasound of Patient 2 showed enlarged kidneys with diffuse microcysts resembling those of autosomal recessive polycystic kidney disease. Her renal histopathology revealed dysplastic kidney with diffuse glomerular cysts. Genetic testing identified compound heterozygous mutations in WDR19 in both patients (Patient 1: c.953delA, c.3533G > A, Patient 2: c.2645 + 1G > T, c.3533G > A). Our patients suggest that WDR19 mutations can cause dysplastic kidney in addition to nephronophthisis pathologically. In addition, differences in pathology of the kidneys from WDR19 mutations may result in heterogeneous features in renal ultrasound findings. Renal phenotypes from WDR19 mutations may thus be more diverse than previously reported. Extrarenal manifestations and genetic testing can therefore help to diagnosis this disease more precisely.
- 15 June 2017
- Published by Wiley in Nephrology
- Vol. 22 (7) , 566-571
Diversity of renal phenotypes in patients with WDR19 mutations: Two case reports
WDR19 has been reported as a causative gene of nephronophthisis‐related ciliopathies. Patients with WDR19 mutations can show various extrarenal manifestations such as skeletal disorders, Caroli disease, and retinal dystrophy, and typically display nephronophthisis as a renal phenotype. However, there is limited information on the renal phenotypes of patients with WDR19 mutations. We report two Japanese infants with Sensenbrenner syndrome caused by WDR19 mutations who demonstrated different features in renal ultrasound and histopathological results, despite several common extrarenal manifestations. Patient 1 had normal sized and hyperechogenic kidneys with several small cysts and histopathological findings compatible with infantile nephronophthisis. Renal ultrasound of Patient 2 showed enlarged kidneys with diffuse microcysts resembling those of autosomal recessive polycystic kidney disease. Her renal histopathology revealed dysplastic kidney with diffuse glomerular cysts. Genetic testing identified compound heterozygous mutations in WDR19 in both patients (Patient 1: c.953delA, c.3533G > A, Patient 2: c.2645 + 1G > T, c.3533G > A). Our patients suggest that WDR19 mutations can cause dysplastic kidney in addition to nephronophthisis pathologically. In addition, differences in pathology of the kidneys from WDR19 mutations may result in heterogeneous features in renal ultrasound findings. Renal phenotypes from WDR19 mutations may thus be more diverse than previously reported. Extrarenal manifestations and genetic testing can therefore help to diagnosis this disease more precisely.